Lilly(LLY)2025-02-19 15:10Workforce and Human Capital Management - At the end of 2024, the company employed approximately 47,000 people, with around 25,000 employees located outside the U.S.[109] - The workforce includes approximately 11,000 individuals engaged in research and development activities[109] - The company values integrity, excellence, and respect for people in its human capital management strategy[106] - The company is committed to fairness and nondiscrimination in employment practices, emphasizing the importance of diverse backgrounds and skills[110] - The company conducts regular confidential employee surveys to gather feedback and improve employee experience[108] - The company aims to foster a healthy work environment by implementing best-in-class safety practices and continuously improving safety performance[111] - The board of directors regularly engages with management to monitor human capital management initiatives[110] - The company believes its dedication to promoting inclusion strengthens its innovation capabilities[110] Research and Development - The company employed approximately 11,000 people in pharmaceutical research and development activities by the end of 2024[87] - The company focuses its internal pharmaceutical research on immunology, metabolism, neuroscience, and oncology[88] - The pharmaceutical development process can take over a decade from discovery to regulatory approval, with a very low probability of candidates becoming approved medicines[90] - The company collaborates with academic institutions and other pharmaceutical companies to enhance its research and development efforts[89] Manufacturing and Supply Chain - The company has undertaken significant manufacturing expansion initiatives across multiple locations, including North Carolina, Wisconsin, Ireland, Germany, and Indiana[97] - The company relies on China-based suppliers for portions of its supply chain, which poses risks due to potential geopolitical tensions and trade restrictions[97] - In 2024, demand for the company's incretin medicines exceeded production capacity, highlighting supply chain challenges[99] Quality and Safety - The company emphasizes a total commitment to quality across all operations, including research, manufacturing, and distribution[100] - The company emphasizes a holistic approach to safety, which it believes enhances its ability to fulfill its purpose of improving lives globally[111] Communication and Transparency - The company provides free access to its SEC filings, including Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, through its website[112] - The company utilizes its website and social media channels to disclose material information and communicate with investors[114]